[go: up one dir, main page]

US20140011884A1 - Use of s1p receptor modulator - Google Patents

Use of s1p receptor modulator Download PDF

Info

Publication number
US20140011884A1
US20140011884A1 US13/893,295 US201313893295A US2014011884A1 US 20140011884 A1 US20140011884 A1 US 20140011884A1 US 201313893295 A US201313893295 A US 201313893295A US 2014011884 A1 US2014011884 A1 US 2014011884A1
Authority
US
United States
Prior art keywords
alkyl
receptor modulator
bdnf
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/893,295
Inventor
Yves-Alain Barde
Graeme Bilbe
Ruben Deogracias
KUHN Rainer R
Tomoya Matsumoto
Anis Khusro Mir
Anna Svenja Schubart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39588961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20140011884(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US13/893,295 priority Critical patent/US20140011884A1/en
Publication of US20140011884A1 publication Critical patent/US20140011884A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of an S1P receptor modulator in the treatment or prevention of a peripheral nervous system disorder, such as Guillan Barre syndrome (GBS)
  • GBS Guillan Barre syndrome
  • BDNF brain-derived neurotrophic factor
  • S1P receptor modulators can induce BDNF production.
  • BDNF has been known as a therapeutic agent for treatment of neurodegenerative diseases (e.g., ALS) or diabetic peripheral neuropathy. BDNF has also been described to be useful as a therapeutic agent for treatment of diabetic mellitus.
  • neurodegenerative diseases e.g., ALS
  • diabetic peripheral neuropathy e.g., diabetic peripheral neuropathy
  • S1P receptor modulators can be employed to treat such conditions affected by BDNF, i.e. conditions which can be treated, delayed or prevented by the increased expression of BDNF.
  • BDNF brain-derived neurotrophic factor
  • the top panel ( FIG. 2A ) shows the induction of BDNF in the pre-frontal cortex of female DA rats.
  • the bottom panel FIG. 2B ) shows the induction of BDNF in the parietal cortex of female DA rats.
  • FIG. 3 shows the results of a study wherein neuronal cultures were established using neurons from different brain regions. The cells were cultured for a total period of 21 days and FTY720-P was added for the last 6 days of the culture period. As with the results shown in FIGS. 1 and 2 , BDNF levels were measured by Western blot and normalised to the level observed in the vehicle control.
  • FIG. 3A shows the results of the assay in CTX neurons.
  • FIG. 3B shows the results of the assay in STR neurons.
  • FIG. 3C shows the results of the assay in HIP neurons.
  • FIG. 4 shows the results of a study similar to that shown in FIG. 3 , but using a broader range of concentrations of FTY720P (all in nM).
  • FIG. 4A shows the results of the assay in CTX neurons.
  • FIG. 4B shows the results of the assay in HIP neurons.
  • FIG. 6 shows the changes from baseline in the BDI-II scores of the 281 patients in the study referred to above in the description of FIG. 5 .
  • S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula Y.
  • Sphingosine-1 phosphate is a natural serum lipid.
  • S1P receptors There are eight known S1P receptors, namely S1 P1 to S1P8, S1 P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula Y
  • Z is H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, phenyl substituted by OH, C 1-6 alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C 3-8 cycloalkyl, phenyl and phenyl substituted by OH, or CH 2 —R 4 , wherein R 4z is OH, acyloxy or a residue of formula (a)
  • Z 1 is a direct bond or O, preferably O;
  • each of R 5z and R 6z is H, or C 1-4 alkyl optionally substituted by 1, 2 or 3 halogen atoms;
  • R 1z is OH, acyloxy or a residue of formula (a); and each of R 2z and R 3z independently, is H, C 1-4 alkyl or acyl.
  • Group of formula Y is a functional group attached as a terminal group to a moiety which may be hydrophilic or lipophilic and comprise one or more aliphatic, alicyclic, aromatic and/or heterocyclic residues, to the extent that the resulting molecule wherein at least one of Z and R 1z is or comprises a residue of formula (a), signals as an agonist at one of more sphingosine-1-phosphate receptor.
  • S1P receptor modulators are compounds which signal as agonists at one or more sphingosine-1 phosphate receptors, e.g. S1 P1 to S1P8.
  • Agonist binding to a S1 P receptor may e.g. result in dissociation of intracellular heterotrimeric G-proteins into G ⁇ -GTP and G ⁇ -GTP, and/or increased phosphorylation of the agonist-occupied receptor and activation of downstream signaling pathways/kinases.
  • the binding affinity of S1P receptor modulators to individual human S1P receptors may be determined in following assay:
  • S1P receptor modulator activities of compounds are tested on the human S1P receptors S1P 1 , S1P 2 , S1P 3 , S1P 4 and S1P 5 , Functional receptor activation is assessed by quantifying compound induced GTP [ ⁇ - 35 S] binding to membrane protein prepared from transfected CHO or RH7777 cells stably expressing the appropriate human S1P receptor.
  • the assay technology used is SPA (scintillation proximity based assay).
  • DMSO dissolved compounds are serially diluted and added to SPA-bead (Amersham-Pharmacia) immobilised S1P receptor expressing membrane protein (10-20 ⁇ g/well) in the presence of 50 mM Hepes, 100 mM NaCl, 10 mM MgCl 2 , 10 ⁇ M GDP, 0.1% fat free BSA and 0.2 nM GTP [ ⁇ - 35 S] (1200 Ci/mmol). After incubation in 96 well microtiterplates at RT for 120 min, unbound GTP [ ⁇ - 35 S] is separated by a centrifugation step. Luminescence of SPA beads triggered by membrane bound GTP [ ⁇ - 35 S] is quantified with a TOPcount plate reader (Packard). EC 50 s are calculated using standard curve fitting software. In this assay, the S1P receptor modulators preferably have a binding affinity to S1P receptor ⁇ 50 nM.
  • Preferred S1P receptor modulators are e.g. compounds which in addition to their S1P binding properties also have accelerating lymphocyte homing properties, e.g. compounds which elicit a lymphopenia resulting from a re-distribution, preferably reversible, of lymphocytes from circulation to secondary lymphatic tissue, without evoking a generalized immunosuppression.
  • Na ⁇ e cells are sequestered; CD4 and CD8 T-cells and B-cells from the blood are stimulated to migrate into lymph nodes (LN) and Peyer's patches (PP).
  • the lymphocyte homing property may be measured in following Blood Lymphocyte Depletion assay:
  • a S1P receptor modulator or the vehicle is administered orally by gavage to rats.
  • Tail blood for hematological monitoring is obtained on day—1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application.
  • the S1P receptor agonist or modulator depletes peripheral blood lymphocytes, e.g. by 50%, when administered at a dose of e.g. ⁇ 20 mg/kg.
  • S1P receptor modulators are, for example:
  • X is O, S, SO or SO 2 ;
  • R 1 is halogen, trihalomethyl, OH, C 1-7 alkyl, C 1-4 alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, CH 2 —OH, CH 2 —CH 2 —OH, C 1-4 alkylthio, C 1-4 alkylsulfinyl, C 1-4 alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC 1-4 alkyl or phenyl-C 1-4 alkoxy each phenyl group thereof being optionally substituted by halogen, CF 3 , C 1-4 alkyl or C 1-4 alkoxy;
  • R 2 is H, halogen, trihalomethyl, C 1-4 alkoxy, C 1-7 alkyl, phenethyl or benzyloxy;
  • R 3 H, halogen, CF 3 , OH, C 1-7 alkyl, C 1-4 alkoxy, benzyloxy, phenyl or C 1-4 alkoxymethyl; each of R 4 and R 5 , independently is H or a residue of formula (a)
  • each of R 8 and R 9 independently, is H or C 1-4 alkyl optionally substituted by halogen;
  • n is an integer from 1 to 4.
  • halogen encompasses fluorine, chlorine, bromine and iodine.
  • trihalomethyl group encompasses trifluoromethyl and trichloromethyl.
  • C 1-7 alkyl encompasses straight-chained or branched alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl or heptyl.
  • substituted or unsubstituted phenoxy group encompasses those that have, at any position of its benzene ring, a halogen atom, such as fluorine, chlorine, bromine and iodine, trifluoromethyl, C 1-4 alkyl or C 1-4 alkoxy.
  • aralkyl group as in “aralkyl group” or “aralkyloxy group” encompasses benzyl, diphenylmethyl, phenethyl and phenylpropyl.
  • any alkyl moiety as present in “C 1-4 alkoxy”, “C 1-4 alkylthio”, “C 1-4 alkylsulfinyl” or “C 1-4 alkylsulfonyl encompasses straight-chained or branched C 1-4 alkyl, e.g. methyl, ethyl, propyl, isopropyl or butyl.
  • substituted or unsubstituted aralkyl group encompasses those that have, at any position of its benzene ring, a halogen atom, such as fluorine, chlorine, bromine and iodine, trifluoromethyl, lower alkyl having 1-4 carbon atoms, or lower alkoxy having 1-4 carbon atoms.
  • a halogen atom such as fluorine, chlorine, bromine and iodine, trifluoromethyl, lower alkyl having 1-4 carbon atoms, or lower alkoxy having 1-4 carbon atoms.
  • R 2 , R 3 , R 4 , R 5 and n are as defined above;
  • R 6 is hydrogen, halogen, C 1-7 alkyl, C 1-4 alkoxy or trifluoromethyl.
  • R 3 is chlorine, e.g., 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-ethyl-propane-1,3-diol, 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl]propyl-1,3-propane-diol or 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]propyl-1,3-propane-diol or a pharmacological salts or hydrates thereof and theirs corresponding phosphate derivatives.
  • phosphoric acid mono-2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-propyl]ester is also exemplified.
  • the phosphoric acid mono-2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-propyl]ester can be prepared enantiomerically pure by the procedures described in WO 2005/021503.
  • Preferred compounds of formula (IIa) are those wherein R 3 is chlorine, e.g., 2-amino-4-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylbutane-1-ol; the corresponding phosphoric acid mono-2-amino-4-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylbutyl]ester; 2-amino-4-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-ethylbutane-1-ol; and the corresponding phosphoric acid mono-2-amino-4-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-ethylbutyl]ester.
  • Phosphorylated derivatives of compounds of formula (I) can be prepared utilizing the procedures for synthesizing phosphorylated compounds described e.g., in WO 2005/021503 (see, e.g., pages 11 and 12).
  • Optically active compounds of structural formula (I) and phosphorylated derivatives thereof, in particular of formula (Ia) can be prepared in high purity utilizing the procedure described, e.g., in Schuding et al., Synthesis, Vol. 11, pp. 1667-1670 (2003).
  • an optically active compound of structural formula (Ia), phosphoric acid mono-2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-propyl]ester can be prepared as described in the scheme below utilizing the procedures of Schuding et al. (2003) supra.
  • R 1 is a straight- or branched (C 12-22 )chain
  • alkyl moiety may have
  • each of R 2 , R 3 , R 4 and R 5 is H, C 1-4 alkyl or acyl
  • R′ 2 , R′ 3 , R′ 4 and R′ 5 independently, is H, C 1-6 alkyl or acyl
  • W is H; C 1-6 alkenyl, C 2-6 alkenyl or C 2-6 alkynyl; unsubstituted or by OH substituted phenyl; R′′ 4 O(CH 2 ) n ; or C 1-6 alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C 3-8 cycloalkyl, phenyl and phenyl substituted by OH;
  • X is H or unsubstituted or substituted straight chain alkyl having a number p of carbon atoms or unsubstituted or substituted straight chain alkoxy having a number (p-1) of carbon atoms, e.g.
  • each of p and q independently, is an integer of 1 to 20, with the proviso of 6 ⁇ p+q ⁇ 23, m′ is 1, 2 or 3, n is 2 or 3,
  • each of R′′ 1 , R′′ 2 , R ′′ 3 and R′′ 4 independently, is H, C 1-4 alkyl or acyl,
  • X a is O, S, NR 1s or a group —(CH 2 ) na —, which group is unsubstituted or substituted by 1 to 4 halogen; n, is 1 or 2, R 1s is H or (C 1-4 )alkyl, which alkyl is unsubstituted or substituted by halogen; R 1a is H, OH, (C 1-4 )alkyl or O(C 1-4 )alkyl wherein alkyl is unsubstituted or substituted by 1 to 3 halogen; is H, OH or (C 1 —)alkyl, wherein alkyl is unsubstituted or substituted by halogen; each R 2a is independently selected from H or (C 1-4 )alkyl, which alkyl is unsubstituted or substituted by halogen; R 3a is H, OH, halogen or O(C 1-4 )alkyl wherein alkyl is unsubstituted
  • each of R 1d and R 2d independently, is H or an amino-protecting group
  • R 3d is hydrogen, a hydroxy-protecting group or a residue of formula
  • R 4d is C 1-4 alkyl
  • n d is an integer of 1 to 6;
  • X d is ethylene, vinylene, ethynylene, a group having a formula -D-CH 2 — (wherein D is carbonyl, —CH(OH)—, O, S or N), aryl or aryl substituted by up to three substitutents selected from group a as defined hereinafter;
  • Y d is single bond, C 1-10 alkylene, C. 1-10 alkylene which is substituted by up to three substitutents selected from groups a and b, C 1-10 alkylene having O or S in the middle or end of the carbon chain, or C 1-10 alkylene having O or S in the middle or end of the carbon chain which is substituted by up to three substituents selected from groups a and b;
  • R 5d is hydrogen, C 3-6 cycloalkyl, aryl, heterocyclic group, C 3-6 cycloalkyl substituted by up to three substituents selected from groups a and b, aryl substituted by up to three substituents selected from groups a and b, or heterocyclic group substituted by up to three substituents selected from groups a and b;
  • each of R 6d and R 7d is H or a substituent selected from group a;
  • each of R 8d and R 9d is H or C 1-4 alkyl optionally substituted by halogen; ⁇ group a> is halogen, lower alkyl, halogeno lower alkyl, lower alkoxy, lower alkylthio, carboxyl, lower alkoxycarbonyl, hydroxy, lower aliphatic acyl, amino, mono-lower alkylamino, di-C 1-4 alkylamino, acylamino, cyano or nitro; and
  • ⁇ group b> is C 3-6 cycloalkyl, aryl or heterocyclic group, each being optionally substituted by up to three substituents selected from group a;
  • R 5d is hydrogen
  • Y d is a either a single bond or linear C 1-10 alkylene, or a pharmacologically acceptable salt, ester or hydrate thereof;
  • R 1e ,R 2e ,R 3e ,R 4e ,R 5e ,R 6e ,R 7e , n, X e and Y e are as disclosed in JP-14315985;
  • Ar is phenyl or naphthyl; each of m g and n g independently is 0 or 1; A is selected from COOH, PO 3 H 2 , PO 2 H, SO 3 H, PO(C 1-3 alkyl)OH and 1H-tetrazol-5-yl; each of R 1g and R 2g independently is H, halogen, OH, COOH or C 1-4 alkyl optionally substituted by halogen; R 3g is H or C 1-4 alkyl optionally substituted by halogen or OH; each R 4g independently is halogen, or optionally halogen substituted C 1-4 alkyl or C 1-3 alkoxy; and each of R g and M has one of the significances as indicated for B and C, respectively, in WO03/062252A1;
  • Ar is phenyl or naphthyl; n is 2,3 or 4; A is COOH, 1H-tetrazol-5-yl, PO 3 H 2 , PO 2 H 2 , —SO 3 H or PO(R 5h )OH wherein R 5h is selected from C 1-4 alkyl, hydroxyC 1-4 alkyl, phenyl, —CO—C 1-3 alkoxy and —CH(OH)-phenyl wherein said phenyl or phenyl moiety is optionally substituted; each of R 1h and R 2h independently is H, halogen, OH, COOH, or optionally halogeno substituted C 1-6 alkyl or phenyl; R 3h is H or C 1-4 alkyl optionally substituted by halogen and/OH; each R 4h independently is halogen, OH, COOH, C 1-4 alkyl, S(O) 0,1 or 2 C 1-3 alkyl, C 1-3 alkoxy, C 3-6 cyclo
  • a k is COOR 5k , OPO(OR 5k ) 2 , PO(OR 5k ) 2 , SO 2 OR 5k , POR 5k OR 5k or 1H-tetrazol-5-yl, R 5k being H or C 1-6 alkyl;
  • W k is a bond, C 1-3 alkylene or C 2-3 alkenylene:
  • Y k is C 6-10 aryl or C 3-9 heteroaryl, optionally substituted by 1 to 3 radicals selected from halogene, OH, NO 2 , C 1-6 alkyl, C 1-6 alkoxy; halo-substituted C 1-6 alkyl and halo-substituted C 1-6 alkoxy;
  • Z k is a heterocyclic group as indicated in WO 04/103306A, e.g. azetidine;
  • R 1k is C 6-10 aryl or C 3-9 heteroaryl, optionally substituted by C 1-6 alkyl, C 6-10 aryl, C 6-10 arylC 1-4 alkyl, C 3-9 heteroaryl, C 3-9 heteroarylC 1-4 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylC 1-4 alkyl,
  • any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R 1k may be substituted by 1 to 5 groups selected from halogen, C 1-6 alkyl, C 1-6 alkoxy and halo substituted-C 1-6 alkyl or —C 1-6 alkoxy;
  • R 2 k is H, C 1-6 alkyl, halo substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl: and
  • each of R 3k or R 4k is H, halogen, OH, C 1-6 alkyl, C 1-6 alkoxy or halo substituted C 1-6 alkyl or C 1-6 alkoxy;
  • the compounds of formulae III to XIb may exist in free or salt form.
  • pharmaceutically acceptable salts of the compounds of the formulae III to VIII include salts with inorganic acids, such as hydrochloride, hydrobromide and sulfate, salts with organic acids, such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate and benzenesulfonate salts, or, when appropriate, salts with metals such as sodium, potassium, calcium and aluminium, salts with amines, such as triethylamine and salts with dibasic amino acids, such as lysine.
  • the compounds and salts of the combination of the present invention encompass hydrate and solvate forms.
  • Acyl as indicated above may be a residue R y —CO— wherein R y is C 1-6 alkyl, C 3-6 cycloalkyl, phenyl or phenyl-C 1-4 alkyl. Unless otherwise stated, alkyl, alkoxy, alkenyl or alkynyl may be straight or branched.
  • Aryl may be phenyl or naphthyl, preferably phenyl.
  • the carbon chain as R 1 is substituted, it is preferably substituted by halogen, nitro, amino, hydroxy or carboxy.
  • the carbon chain is interrupted by an optionally substituted phenylene, the carbon chain is preferably unsubstituted.
  • the phenylene moiety is substituted, it is preferably substituted by halogen, nitro, amino, methoxy, hydroxy or carboxy.
  • Preferred compounds of formula III are those wherein R 1 is C 13-20 alkyl, optionally substituted by nitro, halogen, amino, hydroxy or carboxy, and, more preferably those wherein R 1 is phenylalkyl substituted by C 6-14 -alkyl chain optionally substituted by halogen and the alkyl moiety is a C 1-6 alkyl optionally substituted by hydroxy. More preferably, R 1 is phenyl-C 1-6 alkyl substituted on the phenyl by a straight or branched, preferably straight, C 6-14 alkyl chain. The C 6-14 alkyl chain may be in ortho, meta or para, preferably in para.
  • each of R 2 to R 5 is H.
  • heterocyclic group represents a 5- to 7 membered heterocyclic group having 1 to 3 heteroatoms selected from S, O and N.
  • heterocyclic groups include the heteroaryl groups indicated above, and heterocyclic compounds corresponding to partially or completely hydrogenated heteroaryl groups, e.g.
  • heterocyclic groups are 5-or 6-membered heteroaryl groups and the most preferred heteocyclic
  • a preferred compound of formula III is 2-amino-2-tetradecyl-1,3-propanediol.
  • a particularly preferred S1P receptor agonist of formula I is FTY720, i.e. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form (referred to hereinafter as Compound A), e.g. the hydrochloride, as shown:
  • a preferred compound of formula IV is the one wherein each of R′ 2 to R ′ 5 is H and m is 4, i.e. 2-amino-2- ⁇ 2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl ⁇ propane-1,3-diol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound B), e.g the hydrochloride.
  • a preferred compound of formula V is the one wherein W is CH 3 , each of R′′ 1 to R′′ 3 is H, Z 2 is ethylene, X is heptyloxy and Y is H, i.e. 2-amino-4-(4-heptyloxyphenyl)-2-methyl-butanol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound C), e.g. the hydrochloride.
  • Compound C e.g. the hydrochloride.
  • the R-enantiomer is particularly preferred.
  • a preferred compound of formula Via is the FTY720-phosphate (R 2 , is H, R 3q is OH, X, is O, R 1a and R 1b are OH).
  • a preferred compound of formula IVb is the Compound C-phosphate (R 2a is H, R 3b is OH, X, is O, R 1a and R 1b are OH, Y a is O and R 4a is heptyl).
  • a preferred compound of formula V is Compound B-phosphate.
  • a preferred compound of formula VIII is (2R)-2-amino-4-[3-(4-cyclohexyloxybutyl)-benzo[b]thien-6-yl]-2-methylbutan-1-ol.
  • a preferred compound of formula XIa is e.g. 1- ⁇ 4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl ⁇ -azetidine-3-carboxylic acid, or a prodrug thereof.
  • the compounds as described herein may be the direct active substances, or may be prodrugs.
  • the compounds may be phosphorylated forms.
  • S1P receptor modulators have an inhibitory, preventative or delaying effect on conditions associated with or dependent on or affected by levels of BDNF.
  • the compounds as described herein representing the genus of S1P receptor modulators, increase the levels of BDNF, for example, the compounds as described herein stimulate BDNF production.
  • a compound which induces brain-derived neurotrophic factor (BDNF) expression can be used as a therapeutic agent for treatment of nervous system disorders and diseases, or treatment of diabetes mellitus.
  • BDNF brain-derived neurotrophic factor
  • it can be used in the treatment of conditions wherein sensory neurons or retinal ganglion cells are injured.
  • the compounds can be used in the treatment of congenital conditions or neurodegenerative diseases, for example, Alzheimer's disease, Parkinson's disease (the symptoms of Parkinson's disease may be caused by the degeneration of dopaminergic neuron), Parkinson-Plus syndromes (e.g., progressive spranuclear palsy (Steele-Richardson-Olszewski syndromes), olivopontocerebellar atrophy (OPCA), Shy-Drager syndromes (Multiple Systems Atrophy), and Parkinson dementia complex of Guam), Huntington's disease (Huntington's chorea), and Rett Syndrome, but are not limited thereto.
  • Parkinson-Plus syndromes e.g., progressive spranuclear palsy (Steele-Richardson-Olszewski syndromes), olivopontocerebellar atrophy (OPCA), Shy-Drager syndromes (Multiple Systems Atrophy), and Parkinson dementia complex of Guam
  • OPCA olivopontocerebellar atrophy
  • the compounds can be used in the treatment of sensory nerve dysfunction and congenital diseases or neurodegenerative diseases being associated with degenerative of retina.
  • the compounds can be used in the treatment of inherited convulsive paraplegia associated with retina degeneration (Kjellin and Barnard-Scholz syndromes), retinitis pigmentosa, Stargardt disease, Usher syndromes (retinitis pigmentosa accompanied by congenital hearing loss) and Refsum syndrome (retinitis pigmentosa, congenital hearing loss, and polyneuropathy).
  • inherited convulsive paraplegia associated with retina degeneration Kerjellin and Barnard-Scholz syndromes
  • retinitis pigmentosa Stargardt disease
  • Usher syndromes retinitis pigmentosa accompanied by congenital hearing loss
  • Refsum syndrome retinitis pigmentosa, congenital hearing loss, and polyneuropathy
  • the compounds can be used to treat obesity.
  • the compounds may also be used to treat cognitive impairment and/or attention deficit disorder, for example deficits and abnormalities in attention and vigilance, executive functions and memory (for instance working memory and episodic memory).
  • Other disorders relating to cognitive dysfunction include sleep related breathing disorders (SRBD), behavioral impairments, information processing deficits and age-related disorders, Attention-deficit hyperactivity disorder (ADHD), childhood ADHD, adult ADHD, excess daytime somnolence, sleep apnea, traumatic brain injury, neurodegenerative disorders with associated memory and cognitive problems (such as Alzheimer's disease, Lewy body dementia, senile dementia, vascular dementia, Parkinson's disease), chronic fatigue syndrome, fatigue associated with sleep deprivation or prolonged wakefulness, age-related decline in memory and cognitive function (such as mild cognitive impairment), cognitive impairment associated with mood disorders (such as depression) and anxiety, schizophrenia, day time sleepiness associated with narcolepsy.
  • SRBD sleep related breathing disorders
  • ADHD Attention-deficit hyperactivity disorder
  • childhood ADHD childhood ADHD
  • adult ADHD excess daytime somnol
  • the compounds can be used to treat sleep disorders, e.g. narcolepsy, primary insomnia, sleep-awake rhythm disorders (e.g., work-shift syndrome, time-zone syndrome (jet-lag)).
  • sleep disorders e.g. narcolepsy, primary insomnia, sleep-awake rhythm disorders (e.g., work-shift syndrome, time-zone syndrome (jet-lag)).
  • the compounds can be used to treat depressive disorder, e.g. manic-depressive psychosis.
  • the compounds can be useful in making patients feel better.
  • the present invention provides:
  • S1P receptor modulators e.g. the S1P receptor modulators comprising a group of formula Y, in preventing or treating a disease associated with BDNF as hereinabove specified, may be demonstrated in animal test methods as well as in clinic, for example in accordance with the methods hereinafter described.
  • Female DA rats were treated for 9 days (5 days, 2 day pause, 4 days) with FTY720 p.o.
  • Female DA rats were treated for 9 days (5 days, 2 day pause, 4 days) with FTY720 p.o.
  • axis indicates levels of BDNF normalized to control.
  • FTY720 FTY720 (FTY-p) (0.01, 0.1, 1 and 10 nM) for the last 6 days.
  • Cell lysates were collected at 21 days in vitro.
  • Y axis indicates levels of BDNF normalized to control.
  • the BDI-II was administered at baseline, and at 3 and 6 months during the core study and at 12 and 24 months during the extension phase (i.e. 6 and 18 months after the start of the extension phase).
  • This is a 21-item self-report scale measuring various symptoms and attitudes associated with depression. Respondents rate depressive symptoms experienced during the past two weeks on a 4-point scale, coded 0 to 3 by increasing order of severity. A total score across all 21 items can be generated, with lower total scores indicating lower overall severity of depressive symptoms.
  • BDI-II total scores of 14 or above are indicative of clinical depression. Ny reduction in the BDI-II score indicated an Improvement in depression.
  • BDI-II scores during the core study are shown in FIG. 5 , and changes in these scores from baseline during the core study are shown in FIG. 6 .
  • BDI-II scores decreased from baseline in patients receiving FTY720 1.25 mg/day, remained consistent in patients receiving FTY720 5.0 mg/day, and increased in patients on placebo.
  • the change in BD-II scores from baseline in FTY720 1.25 mg/day treated patients was significantly greater than in placebo-treated patients.
  • the difference in changes in BDI-II scores between the two doses of FTY720 was not significant at the 5% level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression.

Description

  • The present invention relates to the use of an S1P receptor modulator in the treatment or prevention of a peripheral nervous system disorder, such as Guillan Barre syndrome (GBS)
  • One of the neurotrophic factors, a brain-derived neurotrophic factor (hereinafter, often referred to as BDNF), is a protein, which is provided from target cells or neurons and glial cells and Schwann cells in the living body, and shows activities to maintain the survival and differentiation of neurons.
  • It has now been surprisingly shown that S1P receptor modulators can induce BDNF production.
  • BDNF has been known as a therapeutic agent for treatment of neurodegenerative diseases (e.g., ALS) or diabetic peripheral neuropathy. BDNF has also been described to be useful as a therapeutic agent for treatment of diabetic mellitus.
  • Therefore, by inducing BDNF production (or stimulating BDNF expression) S1P receptor modulators can be employed to treat such conditions affected by BDNF, i.e. conditions which can be treated, delayed or prevented by the increased expression of BDNF.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the induction of brain-derived neurotrophic factor (BDNF) in the cortex of female DA rats after a 9-day treatment period with 0.3 mg/kg/d FTY720 measured by Western blot. Shown on the y-axis is the relative intensity of BDNF signal of animals treated with FTY720 vs control animals that had received vehicle (i.e., ratio of signal from FTY720-treated rats divided by signal from vehicle-treated rats, n=3 rats/group). On the x axis, the first two bars come from the frontal cortex, the second two from the parietal cortex and in each case the white bar represents the vehicle treated animals and the black bar represents the FTY720 treated animals.
  • FIG. 2 Similar to FIG. 1, FIG. 2 shows the induction of BDNF in the cortex of female DA rats after a 9-day treatment period, but using multiple doses of FTY720. N=3 animals each were treated with either vehicle, 0.1 mg/kg/d FTY720, 0.3 mg/kg/d FTY720 or 1 mg/kg/d FTY720. The top panel (FIG. 2A) shows the induction of BDNF in the pre-frontal cortex of female DA rats. The bottom panel (FIG. 2B) shows the induction of BDNF in the parietal cortex of female DA rats.
  • FIG. 3 shows the results of a study wherein neuronal cultures were established using neurons from different brain regions. The cells were cultured for a total period of 21 days and FTY720-P was added for the last 6 days of the culture period. As with the results shown in FIGS. 1 and 2, BDNF levels were measured by Western blot and normalised to the level observed in the vehicle control. FIG. 3A shows the results of the assay in CTX neurons. FIG. 3B shows the results of the assay in STR neurons. FIG. 3C shows the results of the assay in HIP neurons.
  • FIG. 4 shows the results of a study similar to that shown in FIG. 3, but using a broader range of concentrations of FTY720P (all in nM). FIG. 4A shows the results of the assay in CTX neurons. FIG. 4B shows the results of the assay in HIP neurons.
  • FIG. 5 shows the mean BDI-II (Beck Depression inventory, second edition) scores of patients participating in a 6 month, placebo controlled Phase II trial of FTY720 in 281 patients having relapsing multiple sclerosis, at the beginning and end of such study (i.e., at t=0 months and t =6 months).
  • FIG. 6 shows the changes from baseline in the BDI-II scores of the 281 patients in the study referred to above in the description of FIG. 5.
    •
  • S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula Y.
  • Sphingosine-1 phosphate (hereinafter “S1P”) is a natural serum lipid. Presently there are eight known S1P receptors, namely S1 P1 to S1P8, S1 P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula Y
  • Figure US20140011884A1-20140109-C00001
  • wherein Z is H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, phenyl, phenyl substituted by OH, C1-6alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C3-8cycloalkyl, phenyl and phenyl substituted by OH, or CH2—R4, wherein R4z is OH, acyloxy or a residue of formula (a)
  • Figure US20140011884A1-20140109-C00002
  • wherein Z1 is a direct bond or O, preferably O;
  • each of R5z and R6z, independently, is H, or C1-4alkyl optionally substituted by 1, 2 or 3 halogen atoms;
  • R1z is OH, acyloxy or a residue of formula (a); and each of R2z and R3z independently, is H, C1-4alkyl or acyl.
  • Group of formula Y is a functional group attached as a terminal group to a moiety which may be hydrophilic or lipophilic and comprise one or more aliphatic, alicyclic, aromatic and/or heterocyclic residues, to the extent that the resulting molecule wherein at least one of Z and R1z is or comprises a residue of formula (a), signals as an agonist at one of more sphingosine-1-phosphate receptor.
  • S1P receptor modulators are compounds which signal as agonists at one or more sphingosine-1 phosphate receptors, e.g. S1 P1 to S1P8. Agonist binding to a S1 P receptor may e.g. result in dissociation of intracellular heterotrimeric G-proteins into Gα-GTP and Gβγ-GTP, and/or increased phosphorylation of the agonist-occupied receptor and activation of downstream signaling pathways/kinases.
  • The binding affinity of S1P receptor modulators to individual human S1P receptors may be determined in following assay:
  • S1P receptor modulator activities of compounds are tested on the human S1P receptors S1P1, S1P2, S1P3, S1P4 and S1P5, Functional receptor activation is assessed by quantifying compound induced GTP [γ-35S] binding to membrane protein prepared from transfected CHO or RH7777 cells stably expressing the appropriate human S1P receptor. The assay technology used is SPA (scintillation proximity based assay). Briefly, DMSO dissolved compounds are serially diluted and added to SPA-bead (Amersham-Pharmacia) immobilised S1P receptor expressing membrane protein (10-20 μg/well) in the presence of 50 mM Hepes, 100 mM NaCl, 10 mM MgCl2, 10 μM GDP, 0.1% fat free BSA and 0.2 nM GTP [γ-35S] (1200 Ci/mmol). After incubation in 96 well microtiterplates at RT for 120 min, unbound GTP [γ-35S] is separated by a centrifugation step. Luminescence of SPA beads triggered by membrane bound GTP [γ-35S] is quantified with a TOPcount plate reader (Packard). EC50s are calculated using standard curve fitting software. In this assay, the S1P receptor modulators preferably have a binding affinity to S1P receptor <50 nM.
  • Preferred S1P receptor modulators are e.g. compounds which in addition to their S1P binding properties also have accelerating lymphocyte homing properties, e.g. compounds which elicit a lymphopenia resulting from a re-distribution, preferably reversible, of lymphocytes from circulation to secondary lymphatic tissue, without evoking a generalized immunosuppression. Naïe cells are sequestered; CD4 and CD8 T-cells and B-cells from the blood are stimulated to migrate into lymph nodes (LN) and Peyer's patches (PP).
  • The lymphocyte homing property may be measured in following Blood Lymphocyte Depletion assay:
  • A S1P receptor modulator or the vehicle is administered orally by gavage to rats. Tail blood for hematological monitoring is obtained on day—1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application. In this assay, the S1P receptor agonist or modulator depletes peripheral blood lymphocytes, e.g. by 50%, when administered at a dose of e.g. <20 mg/kg.
  • Examples of appropriate S1P receptor modulators are, for example:
  • Amino alcohol compounds of formula I
  • Figure US20140011884A1-20140109-C00003
  • wherein X is O, S, SO or SO2;
  • R1 is halogen, trihalomethyl, OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, CH2—OH, CH2—CH2—OH, C1-4alkylthio, C1-4alkylsulfinyl, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy;
  • R2 is H, halogen, trihalomethyl, C1-4alkoxy, C1-7alkyl, phenethyl or benzyloxy;
  • R3H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-4alkoxymethyl; each of R4 and R5, independently is H or a residue of formula (a)
  • Figure US20140011884A1-20140109-C00004
  • wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen; and
  • n is an integer from 1 to 4;
  • or a pharmaceutically acceptable salt thereof;
  • or a compound of formula II
  • Figure US20140011884A1-20140109-C00005
  • wherein
      • R1a is halogen, trihalomethyl, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, C1-4alkylsulifinyl, C1-4alkyl-sulfonyl, aralkyl, optionally substituted phenoxy or aralkyloxy;
      • R2a is H, halogen, trihalomethyl, C1-4alkyl, C1-4alkoxy, aralkyl or aralkyloxy;
      • R3a is H, halogen, CF3, C1-4alkyl, C1-4alkoxy, C1-4alkylthio or benzyloxy;
      • R4a is H, C1-4alkyl, phenyl, optionally substituted benzyl or benzoyl, or lower aliphatic C1-5acyl;
      • R5a is H, monohalomethyl, C1-4alkyl, C1-4alkoxy-methyl, C1-4alkyl-thiomethyl, hydroxyethyl, hydroxypropyl, phenyl, aralkyl, C2-4alkenyl or -alkynyl;
      • R6a is H or C1-4alkyl;
      • R7a is H, C1-4alkyl or a residue of formula (a) as defined above,
      • X, is O, S, SO or SO2; and
      • na is an integer of 1 to 4;
  • or a pharmaceutically acceptable salt thereof.
  • With regard to the compounds of formulae (I) and (II), the term “halogen” encompasses fluorine, chlorine, bromine and iodine. The term “trihalomethyl group” encompasses trifluoromethyl and trichloromethyl. “C1-7 alkyl” encompasses straight-chained or branched alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, hexyl or heptyl. The phrase “substituted or unsubstituted phenoxy group” encompasses those that have, at any position of its benzene ring, a halogen atom, such as fluorine, chlorine, bromine and iodine, trifluoromethyl, C1-4alkyl or C1-4alkoxy. The term “aralkyl group” as in “aralkyl group” or “aralkyloxy group” encompasses benzyl, diphenylmethyl, phenethyl and phenylpropyl. Any alkyl moiety as present in “C1-4alkoxy”, “C1-4alkylthio”, “C1-4alkylsulfinyl” or “C1-4alkylsulfonyl encompasses straight-chained or branched C1-4alkyl, e.g. methyl, ethyl, propyl, isopropyl or butyl. The phrase “substituted or unsubstituted aralkyl group” encompasses those that have, at any position of its benzene ring, a halogen atom, such as fluorine, chlorine, bromine and iodine, trifluoromethyl, lower alkyl having 1-4 carbon atoms, or lower alkoxy having 1-4 carbon atoms.
  • Other compounds of formula I are compounds of formula Ia
  • Figure US20140011884A1-20140109-C00006
  • wherein
  • R2, R3, R4, R5 and n are as defined above; and
  • R6 is hydrogen, halogen, C1-7alkyl, C1-4alkoxy or trifluoromethyl.
  • Further preferred compounds of formula (Ia) are those wherein R3 is chlorine, e.g., 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-ethyl-propane-1,3-diol, 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl]propyl-1,3-propane-diol or 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]propyl-1,3-propane-diol or a pharmacological salts or hydrates thereof and theirs corresponding phosphate derivatives. Also exemplified is phosphoric acid mono-2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-propyl]ester. The phosphoric acid mono-2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-propyl]ester can be prepared enantiomerically pure by the procedures described in WO 2005/021503.
  • Other compounds of formula are compounds of formula (IIa)
  • Figure US20140011884A1-20140109-C00007
  • wherein
      • Y is O or S; and
      • R2a, R3a, R5a, R7a and n are as defined above.
  • Preferred compounds of formula (IIa) are those wherein R3 is chlorine, e.g., 2-amino-4-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylbutane-1-ol; the corresponding phosphoric acid mono-2-amino-4-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylbutyl]ester; 2-amino-4-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-ethylbutane-1-ol; and the corresponding phosphoric acid mono-2-amino-4-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-ethylbutyl]ester.
  • Compounds of formulae I and H are known and are disclosed e.g. in WO03/029205, WO 03/029184 and WO04/026817, respectively, the phosphorylated derivatives being disclosed e.g. in WO04/074297, the contents of which being incorporated herein by reference in their entirety. Compounds of formulae I and II may be prepared as disclosed in above cited references.
  • Phosphorylated derivatives of compounds of formula (I), e.g., phosphoric acid mono-2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-propyl]ester, can be prepared utilizing the procedures for synthesizing phosphorylated compounds described e.g., in WO 2005/021503 (see, e.g., pages 11 and 12). Optically active compounds of structural formula (I) and phosphorylated derivatives thereof, in particular of formula (Ia) can be prepared in high purity utilizing the procedure described, e.g., in Hinterding et al., Synthesis, Vol. 11, pp. 1667-1670 (2003). As an example, an optically active compound of structural formula (Ia), phosphoric acid mono-2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-propyl]ester, can be prepared as described in the scheme below utilizing the procedures of Hinterding et al. (2003) supra.
  • Also included are compounds as disclosed in EP627406A1, e.g. a compound of formula III
  • Figure US20140011884A1-20140109-C00008
  • wherein R1 is a straight- or branched (C12-22)chain
      • which may have in the chain a bond or a hetero atom selected from a double bond, a triple bond, O, S, NR6, wherein R6 is H, C1-4alkyl, aryl-C1-4alkyl, acyl or (C1-4alkoxy)carbonyl, and carbonyl, and/or
        • which may have as a substituent C1-4alkoxy, C2-4alkenyloxy, C2-4alkynyloxy, arylC1-4alkyl-oxy, acyl, C1-4alkylamino, C1-4alkylthio, acylamino, (C1-4alkoxy)carbonyl, (C1-4alkoxy)-carbonylamino, acyloxy, (C1-4alkyl)carbamoyl, nitro, halogen, amino, hydroxyimino, hydroxy or carboxy; or
  • R1 is
      • a phenylalkyl wherein alkyl is a straight- or branched (C8-20)carbon chain; or
      • a phenylalkyl wherein alkyl is a straight- or branched (C1-30)carbon chain wherein said phenylalkyl is substituted by
      • a straight- or branched (C5-20)carbon chain optionally substituted by halogen,
      • a straight- or branched (C6-20)alkoxy chain optionally substituted by halogen,
      • a straight- or branched (C6-20)alkenyloxy,
      • phenyl-C1-14alkoxy, halophenyl-C1-4alkoxy, phenyl-C1-14alkoxy-C1-14alkyl, phenoxy-C1-4alkoxy or phenoxy-C1-4alkyl,
      • cycloalkylalkyl substituted by C6-20alkyl,
      • heteroarylalkyl substituted by C6-20alkyl,
      • heterocyclic C6-20alkyl or
      • heterocyclic alkyl substituted by C2-20alkyl,
  • and wherein
  • the alkyl moiety may have
      • in the carbon chain, a bond or a heteroatom selected from a double bond, a triple bond, O, S, sulfinyl, sulfonyl, or NR6, wherein R6 is as defined above, and
      • as a substituent C1-4alkoxy, C2-4alkenyloxy, C2-4alkynyloxy, arylC1-4alkyloxy, acyl, C1-4alkyl-amino, C1-4alkylthio, acylamino, (C1-4alkoxy)carbonyl, (C1-4alkoxy)carbonylamino, acyloxy, (C1-4alkyl)carbamoyl, nitro, halogen, amino, hydroxy or carboxy, and
  • each of R2, R3, R4 and R5, independently, is H, C1-4 alkyl or acyl
  • or a pharmaceutically acceptable salt or hydrate thereof;
      • Compounds as disclosed in EP 1002792A1 e.g. a compound of formula IV
  • Figure US20140011884A1-20140109-C00009
  • wherein m is 1 to 9 and each of R′2, R′3, R′4 and R′5, independently, is H, C1-6alkyl or acyl,
  • or a pharmaceutically acceptable salt or hydrate thereof;
      • Compounds as disclosed in EP0778263 A1, e.g. a compound of formula V
  • Figure US20140011884A1-20140109-C00010
  • wherein W is H; C1-6alkenyl, C2-6alkenyl or C2-6alkynyl; unsubstituted or by OH substituted phenyl; R″4O(CH2)n; or C1-6alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C3-8cycloalkyl, phenyl and phenyl substituted by OH;
  • X is H or unsubstituted or substituted straight chain alkyl having a number p of carbon atoms or unsubstituted or substituted straight chain alkoxy having a number (p-1) of carbon atoms, e.g. substituted by 1 to 3 substitutents selected from the group consisting of C1-6alkyl, OH, C1-5alkoxy, acyloxy, amino, C1-6alkylamino, acylamino, oxo, haloC1-6alkyl, halogen, unsubstituted phenyl and phenyl substituted by 1 to 3 substituents selected from the group consisting of C1-6alkyl, OH, C1-6alkoxy, acyl, acyloxy, amino, C1-6alkylamino, acylamino, haloC1-6alkyl and halogen; Y is H, C1-6alkyl, OH, C1-6alkoxy, acyl, acyloxy, amino, C1-6alkylamino, acylamino, haloC1-6alkyl or halogen, Z2 is a single bond or a straight chain alkylene having a number or carbon atoms of q,
  • each of p and q, independently, is an integer of 1 to 20, with the proviso of 6≦p+q≦23, m′ is 1, 2 or 3, n is 2 or 3,
  • each of R″1, R″2, R″ 3 and R″4, independently, is H, C1-4alkyl or acyl,
  • or a pharmaceutically acceptable salt or hydrate thereof,
      • Compounds as disclosed in WO02/18395, e.g. a compound of formula VIa or VIb
  • Figure US20140011884A1-20140109-C00011
  • wherein Xa is O, S, NR1s or a group —(CH2)na—, which group is unsubstituted or substituted by 1 to 4 halogen; n, is 1 or 2, R1s is H or (C1-4)alkyl, which alkyl is unsubstituted or substituted by halogen; R1a is H, OH, (C1-4)alkyl or O(C1-4)alkyl wherein alkyl is unsubstituted or substituted by 1 to 3 halogen; is H, OH or (C1—)alkyl, wherein alkyl is unsubstituted or substituted by halogen; each R2a is independently selected from H or (C1-4)alkyl, which alkyl is unsubstituted or substituted by halogen; R3a is H, OH, halogen or O(C1-4)alkyl wherein alkyl is unsubstituted or substituted by halogen; and R3b is H, OH, halogen, (C1-4)alkyl wherein alkyl is unsubstituted or substituted by hydroxy, or O(C1-4)alkyl wherein alkyl is unsubstituted or substituted by halogen; Ya is —CH2—, —C(O)—, —CH(OH)—, —C(═NOH)—, O or S, and R4a is (C4-14)alkyl or (C4-14)alkenyl;
  • or a pharmaceutically acceptable salt or hydrate thereof;
      • Compounds as disclosed in WO02/06268A1, e.g. a compound of formula VII
  • Figure US20140011884A1-20140109-C00012
  • wherein each of R1d and R2d, independently, is H or an amino-protecting group;
  • R3d is hydrogen, a hydroxy-protecting group or a residue of formula
  • Figure US20140011884A1-20140109-C00013
  • R4d is C1-4alkyl;
  • nd is an integer of 1 to 6;
  • Xd is ethylene, vinylene, ethynylene, a group having a formula -D-CH2— (wherein D is carbonyl, —CH(OH)—, O, S or N), aryl or aryl substituted by up to three substitutents selected from group a as defined hereinafter;
  • Yd is single bond, C1-10alkylene, C.1-10alkylene which is substituted by up to three substitutents selected from groups a and b, C1-10alkylene having O or S in the middle or end of the carbon chain, or C1-10alkylene having O or S in the middle or end of the carbon chain which is substituted by up to three substituents selected from groups a and b;
  • R5d is hydrogen, C3-6cycloalkyl, aryl, heterocyclic group, C3-6cycloalkyl substituted by up to three substituents selected from groups a and b, aryl substituted by up to three substituents selected from groups a and b, or heterocyclic group substituted by up to three substituents selected from groups a and b;
  • each of R6d and R7d, independently, is H or a substituent selected from group a;
  • each of R8d and R9d, independently, is H or C1-4alkyl optionally substituted by halogen; <group a> is halogen, lower alkyl, halogeno lower alkyl, lower alkoxy, lower alkylthio, carboxyl, lower alkoxycarbonyl, hydroxy, lower aliphatic acyl, amino, mono-lower alkylamino, di-C1-4alkylamino, acylamino, cyano or nitro; and
  • <group b> is C3-6cycloalkyl, aryl or heterocyclic group, each being optionally substituted by up to three substituents selected from group a;
  • with the proviso that when R5d is hydrogen, Yd is a either a single bond or linear C1-10 alkylene, or a pharmacologically acceptable salt, ester or hydrate thereof;
      • Compounds as disclosed in JP-14316985 (JP20023169851 e.g. a compound of formula VII
  • Figure US20140011884A1-20140109-C00014
  • wherein R1e,R2e,R3e,R4e,R5e,R6e,R7e, n, Xe and Ye are as disclosed in JP-14315985;
  • or a pharmacologically acceptable salt, ester or hydrate thereof;
      • Compounds as disclosed in WO031062252A1, e.g. a compound of formula IX
  • Figure US20140011884A1-20140109-C00015
  • wherein
  • Ar is phenyl or naphthyl; each of mg and ng independently is 0 or 1; A is selected from COOH, PO3H2, PO2H, SO3H, PO(C1-3alkyl)OH and 1H-tetrazol-5-yl; each of R1g and R2g independently is H, halogen, OH, COOH or C1-4alkyl optionally substituted by halogen; R3g is H or C1-4alkyl optionally substituted by halogen or OH; each R4g independently is halogen, or optionally halogen substituted C1-4alkyl or C1-3alkoxy; and each of Rg and M has one of the significances as indicated for B and C, respectively, in WO03/062252A1;
  • or a pharmacologically acceptable salt, solvate or hydrate thereof;
      • Compounds as disclosed in WO03/062248A2, e.g. a compound of formula X
  • Figure US20140011884A1-20140109-C00016
  • wherein Ar is phenyl or naphthyl; n is 2,3 or 4; A is COOH, 1H-tetrazol-5-yl, PO3H2, PO2H2, —SO3H or PO(R5h)OH wherein R5h is selected from C1-4alkyl, hydroxyC1-4alkyl, phenyl, —CO—C1-3alkoxy and —CH(OH)-phenyl wherein said phenyl or phenyl moiety is optionally substituted; each of R1h and R2h independently is H, halogen, OH, COOH, or optionally halogeno substituted C1-6alkyl or phenyl; R3h is H or C1-4alkyl optionally substituted by halogen and/OH; each R4h independently is halogen, OH, COOH, C1-4alkyl, S(O)0,1 or 2C1-3alkyl, C1-3alkoxy, C3-6cycloalkoxy, aryl or aralkoxy, wherein the alkyl portions may optionally be substituted by 1-3 halogens; and each of Rn and M has one of the significances as indicated for B and C, respectively, in WO031062248A2
  • or a pharmacologically acceptable salt, solvate or hydrate thereof.
      • Compounds as disclosed in WO 04/103306A, WO 05/000833, WO05/103309 or WO 05/113330, e.g. compounds of formula XIa or XIb
  • Figure US20140011884A1-20140109-C00017
  • wherein
  • Ak is COOR5k, OPO(OR5k)2, PO(OR5k)2, SO2OR5k, POR5kOR5k or 1H-tetrazol-5-yl, R5k being H or C1-6alkyl;
  • Wk is a bond, C1-3alkylene or C2-3alkenylene:
  • Yk is C6-10aryl or C3-9heteroaryl, optionally substituted by 1 to 3 radicals selected from halogene, OH, NO2, C1-6alkyl, C1-6alkoxy; halo-substituted C1-6alkyl and halo-substituted C1-6alkoxy;
  • Zk is a heterocyclic group as indicated in WO 04/103306A, e.g. azetidine;
  • R1k is C6-10aryl or C3-9heteroaryl, optionally substituted by C1-6alkyl, C6-10aryl, C6-10arylC1-4alkyl, C3-9heteroaryl, C3-9heteroarylC1-4alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-4alkyl,
  • C3-8heterocycloalkyl or C3-8heterocycloalkylC1-4alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R1k may be substituted by 1 to 5 groups selected from halogen, C1-6alkyl, C1-6alkoxy and halo substituted-C1-6alkyl or —C1-6alkoxy;
  • R2k is H, C1-6alkyl, halo substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl: and
  • each of R3k or R4k, independently, is H, halogen, OH, C1-6alkyl, C1-6alkoxy or halo substituted C1-6alkyl or C1-6alkoxy;
  • and the N-oxide derivatives thereof or prodrugs thereof,
  • or a pharmacologically acceptable salt, solvate or hydrate thereof.
  • The compounds of formulae III to XIb may exist in free or salt form. Examples of pharmaceutically acceptable salts of the compounds of the formulae III to VIII include salts with inorganic acids, such as hydrochloride, hydrobromide and sulfate, salts with organic acids, such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate and benzenesulfonate salts, or, when appropriate, salts with metals such as sodium, potassium, calcium and aluminium, salts with amines, such as triethylamine and salts with dibasic amino acids, such as lysine. The compounds and salts of the combination of the present invention encompass hydrate and solvate forms.
  • Acyl as indicated above may be a residue Ry—CO— wherein Ry is C1-6alkyl, C3-6cycloalkyl, phenyl or phenyl-C1-4alkyl. Unless otherwise stated, alkyl, alkoxy, alkenyl or alkynyl may be straight or branched.
  • Aryl may be phenyl or naphthyl, preferably phenyl.
  • When in the compounds of formula I the carbon chain as R1 is substituted, it is preferably substituted by halogen, nitro, amino, hydroxy or carboxy. When the carbon chain is interrupted by an optionally substituted phenylene, the carbon chain is preferably unsubstituted. When the phenylene moiety is substituted, it is preferably substituted by halogen, nitro, amino, methoxy, hydroxy or carboxy.
  • Preferred compounds of formula III are those wherein R1 is C13-20alkyl, optionally substituted by nitro, halogen, amino, hydroxy or carboxy, and, more preferably those wherein R1 is phenylalkyl substituted by C6-14-alkyl chain optionally substituted by halogen and the alkyl moiety is a C1-6alkyl optionally substituted by hydroxy. More preferably, R1 is phenyl-C1-6alkyl substituted on the phenyl by a straight or branched, preferably straight, C6-14alkyl chain. The C6-14alkyl chain may be in ortho, meta or para, preferably in para.
  • Preferably each of R2 to R5 is H.
  • In the above formula of VII “heterocyclic group” represents a 5- to 7 membered heterocyclic group having 1 to 3 heteroatoms selected from S, O and N. Examples of such heterocyclic groups include the heteroaryl groups indicated above, and heterocyclic compounds corresponding to partially or completely hydrogenated heteroaryl groups, e.g. furyl, thienyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl or pyrazolidinyl. Preferred heterocyclic groups are 5-or 6-membered heteroaryl groups and the most preferred heteocyclic group is a morpholinyl, thiomorpholinyl or piperidinyl group.
  • A preferred compound of formula III is 2-amino-2-tetradecyl-1,3-propanediol. A particularly preferred S1P receptor agonist of formula I is FTY720, i.e. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form (referred to hereinafter as Compound A), e.g. the hydrochloride, as shown:
  • Figure US20140011884A1-20140109-C00018
  • A preferred compound of formula IV is the one wherein each of R′2 to R′ 5 is H and m is 4, i.e. 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound B), e.g the hydrochloride.
  • A preferred compound of formula V is the one wherein W is CH3, each of R″1 to R″3 is H, Z2 is ethylene, X is heptyloxy and Y is H, i.e. 2-amino-4-(4-heptyloxyphenyl)-2-methyl-butanol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound C), e.g. the hydrochloride. The R-enantiomer is particularly preferred.
  • A preferred compound of formula Via is the FTY720-phosphate (R2, is H, R3q is OH, X, is O, R1a and R1b are OH). A preferred compound of formula IVb is the Compound C-phosphate (R2a is H, R3b is OH, X, is O, R1a and R1b are OH, Ya is O and R4a is heptyl). A preferred compound of formula V is Compound B-phosphate.
  • A preferred compound of formula VIII is (2R)-2-amino-4-[3-(4-cyclohexyloxybutyl)-benzo[b]thien-6-yl]-2-methylbutan-1-ol.
  • A preferred compound of formula XIa is e.g. 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a prodrug thereof.
  • It will be appreciated that the compounds as described herein may be the direct active substances, or may be prodrugs. For example, the compounds may be phosphorylated forms.
  • It has now been found that S1P receptor modulators have an inhibitory, preventative or delaying effect on conditions associated with or dependent on or affected by levels of BDNF.
  • In one particular aspect of the present invention, the compounds as described herein, representing the genus of S1P receptor modulators, increase the levels of BDNF, for example, the compounds as described herein stimulate BDNF production.
  • A compound which induces brain-derived neurotrophic factor (BDNF) expression can be used as a therapeutic agent for treatment of nervous system disorders and diseases, or treatment of diabetes mellitus.
  • More particularly, it is useful for nervous system injured by wound, surgery, ischemia, infection, metabolic diseases, malnutrition, malignant tumor, or toxic drug, etc. Especially, it can be used in the treatment of conditions wherein sensory neurons or retinal ganglion cells are injured.
  • More especially, the compounds can be used in the treatment of congenital conditions or neurodegenerative diseases, for example, Alzheimer's disease, Parkinson's disease (the symptoms of Parkinson's disease may be caused by the degeneration of dopaminergic neuron), Parkinson-Plus syndromes (e.g., progressive spranuclear palsy (Steele-Richardson-Olszewski syndromes), olivopontocerebellar atrophy (OPCA), Shy-Drager syndromes (Multiple Systems Atrophy), and Parkinson dementia complex of Guam), Huntington's disease (Huntington's chorea), and Rett Syndrome, but are not limited thereto.
  • Further, the compounds can be used in the treatment of sensory nerve dysfunction and congenital diseases or neurodegenerative diseases being associated with degenerative of retina.
  • In addition, the the compounds can be used in the treatment of inherited convulsive paraplegia associated with retina degeneration (Kjellin and Barnard-Scholz syndromes), retinitis pigmentosa, Stargardt disease, Usher syndromes (retinitis pigmentosa accompanied by congenital hearing loss) and Refsum syndrome (retinitis pigmentosa, congenital hearing loss, and polyneuropathy).
  • Further, the compounds can be used to treat obesity.
  • The compounds may also be used to treat cognitive impairment and/or attention deficit disorder, for example deficits and abnormalities in attention and vigilance, executive functions and memory (for instance working memory and episodic memory). Other disorders relating to cognitive dysfunction include sleep related breathing disorders (SRBD), behavioral impairments, information processing deficits and age-related disorders, Attention-deficit hyperactivity disorder (ADHD), childhood ADHD, adult ADHD, excess daytime somnolence, sleep apnea, traumatic brain injury, neurodegenerative disorders with associated memory and cognitive problems (such as Alzheimer's disease, Lewy body dementia, senile dementia, vascular dementia, Parkinson's disease), chronic fatigue syndrome, fatigue associated with sleep deprivation or prolonged wakefulness, age-related decline in memory and cognitive function (such as mild cognitive impairment), cognitive impairment associated with mood disorders (such as depression) and anxiety, schizophrenia, day time sleepiness associated with narcolepsy.
  • In addition, the compounds can be used to treat sleep disorders, e.g. narcolepsy, primary insomnia, sleep-awake rhythm disorders (e.g., work-shift syndrome, time-zone syndrome (jet-lag)).
  • In additions, the compounds can be used to treat depressive disorder, e.g. manic-depressive psychosis.
  • In a further use, the compounds can be useful in making patients feel better.
  • In a series of further specific or alternative embodiments, the present invention provides:
      • 1.1 A method for preventing, inhibiting or treating a condition effected by BDNF production, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb.
      • 1.2 A method for alleviating or delaying progression of the symptoms of obesity, a sleep disorder or depressive disorder, in a subject in need thereof, in which method the BDNF-dependent factor associated with said disease is prevented or inhibited, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb.
      • 1.3 A method for inducing the production of BDNF, in a subject, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb.
      • 1.4 A method for slowing progression of obesity, a sleep disorder or depressive disorder, in a subject, in which method the BDNF-dependent factor associated with said disease is prevented or inhibited, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb.
      • 1.5 A method as indicated above, wherein the S1P receptor modulator is administered intermittently.
        • For example, the S1P receptor modulator may be administered to the subject every 2nd or 3rd day or once a week.
      • 2. A pharmaceutical composition for use in any one of the methods 1.1 to 1.5, comprising an S1P receptor modulator, e.g. a compound of formulae I to XIb as defined hereinabove, together with one or more pharmaceutically acceptable diluents or carriers therefor.
      • 3. An S1P receptor modulator, e.g. a compound of formula I to XIb as defined herein above, for use in any one of the methods 1.1 to 1.5.
      • 4. An S1P receptor modulator, e,g. a compound of formulae 1 to XIb as defined herein above, for use in the preparation of a medicament for use in any one of the methods 1.1 to 1.5.
  • Utility of the S1P receptor modulators, e.g. the S1P receptor modulators comprising a group of formula Y, in preventing or treating a disease associated with BDNF as hereinabove specified, may be demonstrated in animal test methods as well as in clinic, for example in accordance with the methods hereinafter described.
    • EXAMPLE 1 In Vivo: S1P Receptor Modulator Induced BDNF Production
  • Female DA rats were treated for 9 days (5 days, 2 day pause, 4 days) with FTY720 p.o.
  • Expt 1: 0.3 mg/kg/d vs. vehicle.
  • N=3 rats/group
  • One day after the last treatment, the rats were perfused with ice-cold PBS and different CNS regions were isolated.
  • The results are shown in FIG. 1.
    • EXAMPLE 2 In Vivo: S1P Receptor Modulator Induced BDNF Production
  • Female DA rats were treated for 9 days (5 days, 2 day pause, 4 days) with FTY720 p.o.
  • 0,1; 0.3 or 1 mg/kg/d vs vehicle
  • N=3 rats/group
  • One day after the last treatment, the rats were perfused with ice-cold PBS and different CNS regions were isolated.
  • The results are shown in FIG. 2.
    • EXAMPLE 3 In Vitro: S1P Receptor Modulator Induced BDNF Production
  • Effect of FTY720 on BDNF expression in cultured CTX, STR, and HIP neurons was investigated.
  • Neurons were treated with phosphorylated FTY720 (FTY-p) (1 and 10 nM) for the last 6 days.
  • Cell lysates were collected at 21 days in vitro,
  • axis indicates levels of BDNF normalized to control.
  • *P<0.05 vs DMSO
  • The results are shown in FIGS. 3A, B and C.
    • EXAMPLE 4 In Vitro: S1P Receptor Modulator Induced BDNF Production
  • Effect of FTY720 on BDNF expression in cultured CTX and HIP neurons was investigated.
  • Neurons were treated with FTY720 (FTY-p) (0.01, 0.1, 1 and 10 nM) for the last 6 days. Cell lysates were collected at 21 days in vitro.
  • Y axis indicates levels of BDNF normalized to control.
  • The results are shown in FIG. 4.
    • EXAMPLE 5 Clinical Trial: S1P Receptor Modulator made People Feel Better
  • In a 6-month, placebo controlled, Phase II trial involving 281 patients with relapsing MS, FTY720 reduced gadolinium-enhanced magnetic resonance imaging (MRI) lesions by up to 80%, and the annualized relapse rate by more than 50%, compared with placebo, at doses of 1.25 and 5 mg once daily.3 The resulting low disease activity on both MRI and relapses was sustained in patients treated with FTY720 for up to 24 months during a dose-blinded extension phase. Patients who received placebo also had marked improvements after switching to FTY720 in the extension.
  • In this study, depressive symptoms were assessed by means of the Beck Depression Inventory second edition (BDI-II). These results are presented here.
  • Method
  • Patients with relapsing MS (relapsing-remitting or secondary progressive) were randomized to receive placebo or FTY720 1.25 or 5 mg/day, for 6 months (the core study). At the end of this period, placebo-treated patients were re-randomized to one of the two FTY720 doses, while those originally randomized to FTY720 continued treatment at the same doses. After approximately 18-24 months, patients receiving FTY720 5 mg, were switched to 1.25 mg in view of evidence that the higher dose conferred no efficacy benefit over the lower dose.
  • The BDI-II was administered at baseline, and at 3 and 6 months during the core study and at 12 and 24 months during the extension phase (i.e. 6 and 18 months after the start of the extension phase). This is a 21-item self-report scale measuring various symptoms and attitudes associated with depression. Respondents rate depressive symptoms experienced during the past two weeks on a 4-point scale, coded 0 to 3 by increasing order of severity. A total score across all 21 items can be generated, with lower total scores indicating lower overall severity of depressive symptoms. BDI-II total scores of 14 or above are indicative of clinical depression. Ny reduction in the BDI-II score indicated an Improvement in depression.
  • Results
  • Patients
  • Of the 281 patients originally randomized to treatment, 255 completed the core study. BDI-II scores at baseline and 6 months were available in 239 patients.
  • Changes in BDI-II Scores During the Core Study
  • Mean BDI-II scores during the core study are shown in FIG. 5, and changes in these scores from baseline during the core study are shown in FIG. 6. BDI-II scores decreased from baseline in patients receiving FTY720 1.25 mg/day, remained consistent in patients receiving FTY720 5.0 mg/day, and increased in patients on placebo. At 6 months, the change in BD-II scores from baseline in FTY720 1.25 mg/day treated patients was significantly greater than in placebo-treated patients. The difference in changes in BDI-II scores between the two doses of FTY720 was not significant at the 5% level.

Claims (10)

1. A method for preventing, inhibiting or treating a condition effected by BDNF production, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb as defined hereinabove.
2. The method of claim 1, where the condition affected by BDNF production is selected from one or more of diabetes, nervous system injured by wound, congenital conditions, neurodegenerative diseases, sensory nerve dysfunction, obesity, cognitive impairment, attention deficit disorders, sleep disorders or depressive disorders.
3. A method for inducing the production of BDNF, in a subject, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb.
4. A method for making a patient feel better, e.g. by removing symptoms of depression, comprising administering to said subject a therapeutically effective amount of an S1P receptor modulator, e.g. a compound of formulae I to XIb.
5. A method according to claim 1, wherein the S1P receptor modulator is administered intermittently.
6. A pharmaceutical composition for use in a method according to claim 1, comprising an S1P receptor modulator, e.g. a compound of formulae I to XIb as defined hereinabove, together with one or more pharmaceutically acceptable diluents or carriers therefor.
7. A method according to claim 1 comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective non-toxic amount of a S1P receptor modulator and a second therapeutic substance.
8. A pharmaceutical combination, e.g. a kit, comprising a) a first agent which is a S1P receptor modulator e.g. a compound of formulae I to XIb as defined herein above, in free form or in pharmaceutically acceptable salt form, and b) instructions for use in a BDNF-related condition or disease, as described herein.
9. The combination of claim 7, wherein the BDNF-related condition or disease selected from one or more of diabetes, nervous system injured by wound, congenital conditions, neurodegenerative diseases, sensory nerve dysfunction, obesity, cognitive impairment, attention deficit disorders, sleep disorders or depressive disorders.
10. A method according to claim 1, wherein the S1P receptor modulator is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form.
US13/893,295 2007-05-04 2013-05-13 Use of s1p receptor modulator Abandoned US20140011884A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/893,295 US20140011884A1 (en) 2007-05-04 2013-05-13 Use of s1p receptor modulator

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91598507P 2007-05-04 2007-05-04
PCT/EP2008/055405 WO2008135522A1 (en) 2007-05-04 2008-05-01 Use of s1p receptor modulator
US59877109A 2009-11-04 2009-11-04
US13/893,295 US20140011884A1 (en) 2007-05-04 2013-05-13 Use of s1p receptor modulator

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2008/055405 Continuation WO2008135522A1 (en) 2007-05-04 2008-05-01 Use of s1p receptor modulator
US59877109A Continuation 2007-05-04 2009-11-04

Publications (1)

Publication Number Publication Date
US20140011884A1 true US20140011884A1 (en) 2014-01-09

Family

ID=39588961

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/598,771 Abandoned US20100093672A1 (en) 2007-05-04 2008-05-01 Use of s1p receptor modulator
US13/310,941 Abandoned US20120245129A1 (en) 2007-05-04 2011-12-05 Use of s1p receptor modulator
US13/893,295 Abandoned US20140011884A1 (en) 2007-05-04 2013-05-13 Use of s1p receptor modulator
US14/097,623 Active US9265754B2 (en) 2007-05-04 2013-12-05 Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/598,771 Abandoned US20100093672A1 (en) 2007-05-04 2008-05-01 Use of s1p receptor modulator
US13/310,941 Abandoned US20120245129A1 (en) 2007-05-04 2011-12-05 Use of s1p receptor modulator

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/097,623 Active US9265754B2 (en) 2007-05-04 2013-12-05 Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome

Country Status (12)

Country Link
US (4) US20100093672A1 (en)
EP (1) EP2142184B1 (en)
JP (5) JP2010526116A (en)
KR (3) KR20100021430A (en)
CN (2) CN104337808A (en)
AU (1) AU2008248648B2 (en)
BR (1) BRPI0810733A2 (en)
CA (1) CA2684953C (en)
ES (1) ES2707576T3 (en)
MX (1) MX2009011943A (en)
RU (1) RU2498796C2 (en)
WO (1) WO2008135522A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235610A1 (en) * 2007-05-04 2014-08-21 Yves-Alain Barde Use of s1p receptor modulator

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101973898B (en) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-p-octylphenethyl-2-aminopropylene glycol derivative and application thereof
UA114283C2 (en) 2011-01-07 2017-05-25 Новартіс Аг COMPOSITIONS OF IMMUNOSUPRESSANTS
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2846768A1 (en) * 2011-09-13 2013-03-21 Novartis Ag Combinations comprising a s1p receptor modulator
US8946301B2 (en) * 2011-11-29 2015-02-03 Als Therapy Development Institute Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CN106466479A (en) * 2015-08-18 2017-03-01 周意 Brain Derived Neurotrophic Factor precursor protein is used as the target spot for the treatment of affective disorder
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CN118662488A (en) * 2020-02-06 2024-09-20 田边三菱制药株式会社 Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103306A2 (en) * 2003-05-19 2004-12-02 Irm Llc Immunosuppressant compounds and compositions
US20050043534A1 (en) * 2001-07-11 2005-02-24 Alicja Bielawska Modulators of ceramidase and methods of used based thereon

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002237988B2 (en) * 2001-01-30 2008-01-03 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
JP4861177B2 (en) * 2003-09-12 2012-01-25 ニューロノバ エービー Treatment of nervous system disorders
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
EP1755680A1 (en) 2004-05-03 2007-02-28 Novartis AG Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
US20090275553A1 (en) * 2004-11-29 2009-11-05 Kovarik John M Dosage regimen of an s1p receptor agonist
WO2006064616A1 (en) 2004-12-16 2006-06-22 Matsushita Electric Industrial Co., Ltd. Raw garbage disposer
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2007338771A1 (en) * 2006-12-19 2008-07-03 Merrimack Pharmaceuticals, Inc. Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
KR20100021430A (en) * 2007-05-04 2010-02-24 노파르티스 아게 Use of s1p receptor modulator

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043534A1 (en) * 2001-07-11 2005-02-24 Alicja Bielawska Modulators of ceramidase and methods of used based thereon
WO2004103306A2 (en) * 2003-05-19 2004-12-02 Irm Llc Immunosuppressant compounds and compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235610A1 (en) * 2007-05-04 2014-08-21 Yves-Alain Barde Use of s1p receptor modulator
US9265754B2 (en) * 2007-05-04 2016-02-23 Novartis Ag Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome

Also Published As

Publication number Publication date
AU2008248648A1 (en) 2008-11-13
US9265754B2 (en) 2016-02-23
JP2015199756A (en) 2015-11-12
KR20100021430A (en) 2010-02-24
KR20140141716A (en) 2014-12-10
KR101526835B1 (en) 2015-06-05
RU2009144846A (en) 2012-08-10
CN101674819A (en) 2010-03-17
JP5764643B2 (en) 2015-08-19
CA2684953C (en) 2016-08-09
KR20150017391A (en) 2015-02-16
JP2010526116A (en) 2010-07-29
KR101528125B1 (en) 2015-06-11
RU2498796C2 (en) 2013-11-20
JP2014088395A (en) 2014-05-15
WO2008135522A1 (en) 2008-11-13
US20100093672A1 (en) 2010-04-15
CA2684953A1 (en) 2008-11-13
JP2020037567A (en) 2020-03-12
AU2008248648B2 (en) 2012-02-23
MX2009011943A (en) 2009-11-13
BRPI0810733A2 (en) 2014-10-21
EP2142184A1 (en) 2010-01-13
US20120245129A1 (en) 2012-09-27
JP2017105823A (en) 2017-06-15
US20140235610A1 (en) 2014-08-21
EP2142184B1 (en) 2018-10-24
CN104337808A (en) 2015-02-11
ES2707576T3 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
US9265754B2 (en) Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome
JP6931019B2 (en) S1P receptor modulator for treating multiple sclerosis
US20120328664A1 (en) Liquid formulations
US20140066657A1 (en) Dosage regimen for a s1p receptor agonist
NO20121305L (en) Dosage regimen for an S1P receptor agonist
JP2010526116A5 (en)
AU2012200503B2 (en) &#34;Use of S1P receptor modulator&#34;

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION